In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Auris Medical Holding AG

www.aurismedical.com

Latest From Auris Medical Holding AG

People Round-Up: Dipharma And Xellia North America Get New Heads

Dipharma appoints a new CEO, Xellia gets a new commercial head in North America, promotions are made at Lek, GVK Bio and the APhA, while appointments are seen at Auris Medical and Tris Pharma.

Appointments Strategy

Pharma Wakes Up To Transformative Progress In Hearing Loss Research

The cacophony of noise in the modern world is one factor driving the loss of hearing throughout humankind, a condition that until now has not been thought amenable to pharmacological intervention. But with small-molecule approaches to regenerating cells in the inner ear bearing fruit, biotech and pharmaceutical companies are taking renewed interest in the sector. 

Innovation Research and Development Strategies

Pharma Wakes Up To Transformative Progress In Hearing Loss Research

The cacophony of noise in the modern world is one factor driving the loss of hearing throughout humankind, a condition that until now has not been thought amenable to pharmacological intervention. But with small-molecule approaches to regenerating cells in the inner ear bearing fruit, biotech and pharmaceutical companies are taking renewed interest in the sector. 

Research and Development Strategies Research & Development

Protecting Against Hearing Loss: Acousia Pursues A New Approach

German biotech Acousia Therapeutics closes a series B round with corporate and institutional VC firms, and aims to advance its drugs into clinical trials for hearing loss associated with cancer chemotherapy. 

 

Financing Ear
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Otolaryngology
  • Alias(es)
  • Auris Medical AG
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Auris Medical Holding AG
  • Senior Management
  • Thomas Meyer, PhD, CEO
    Elmar Schärli, CFO
  • Contact Info
  • Auris Medical Holding AG
    Phone: 61 201 13 50
    Bahnhofstrasse 21
    Zug, 6300
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register